Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pevonedistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 known ✓ | Q13564 | 18/20 | 1.00 |
| ▸ | UBA3 known ✓ | Q8TBC4 | 16/20 | 1.00 |
| ▸ | UBA6 | A0AVT1 | 3/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | NEDD8 | Q15843 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | ATG7 | O95352 | 1/20 | 0.58 |
| ▸ | UBA7 | P41226 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pevonedistat SCHEMBL14321349 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL10016613 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL10048256 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL14328898 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL23924438 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL15685348 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL23833815 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL1800436 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL20603286 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL22472958 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148728-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-05-09 | — | — | US | claimed |
| EP-4297788-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | Nanyang Technological University (SG) | 2024-01-03 | — | — | EP | claimed |
| US-20230172933-A1 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-06-08 | — | — | US | claimed |
| WO-2022182292-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-01 | — | — | WO | claimed |
| WO-2021188052-A1 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-09-23 | — | — | WO | claimed |
| US-11124519-B2 | Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | claimed |
| US-10953013-B2 | Biomarkers of response to NAE inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-10786505-B2 | Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | claimed |
| EP-2996773-B1 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | MILLENNIUM PHARM INC (US) | 2020-09-16 | — | — | EP | claimed |
| US-20200277294-A1 | COCRYSTAL FORMS OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE, FORMULATIONS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-03 | — | — | US | claimed |
| US-20150240315-A1 | BIOMARKERS AND METHODS TO PREDICT RESPONSE TO INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-27 | — | — | US | claimed |
| US-20150164901-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-06-18 | — | — | US | claimed |
| US-20150119410-A1 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC (US) | 2015-04-30 | — | — | US | claimed |
| US-20150105411-A1 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | claimed |
| US-8980850-B2 | Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2014186388-A2 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | MILLENNIUM PHARMACEUTCALS, INC. (US) | 2014-11-20 | — | — | WO | claimed |
| WO-2013188881-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-12-19 | — | — | WO | claimed |
| US-20130116208-A1 | ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | claimed |
| EP-1989206-B1 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | claimed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116208-A1 | ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT | NEDD8, NAE1, UBE2M | NAE1 2/4885UBA3 4/4885UBA6 174/4885 |
| US-20200277294-A1 | COCRYSTAL FORMS OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE, FORMULATIONS AND USES THEREOF | SULT1E1, SULT1A1, SULT2A1 | NAE1 580/4885UBA3 247/4885UBA6 1828/4885 |
| US-10786505-B2 | Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents | NEDD8, NAE1, CAND1 | NAE1 2/4885UBA3 4/4885UBA6 236/4885 |
| US-20150164901-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, SNCA | NAE1 2998/4885UBA3 2813/4885UBA6 868/4885 |
| US-11124519-B2 | Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof | SULT1E1, SULT1A1, SULT2A1 | NAE1 580/4885UBA3 247/4885UBA6 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.